Top Page
ClearPoint Neuro
(NASDAQ:CLPT)
ClearPoint Neuro (CLPT) vs. SPDR S&P 500 ETF (SPY)
ClearPoint Neuro Business Overview & Revenue Model
ClearPoint Neuro Earnings Call Summary
ClearPoint Neuro Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.24M | 31.39M | 23.95M | 20.55M | 16.30M | 12.83M |
| Gross Profit | 19.73M | 19.12M | 13.61M | 13.53M | 11.29M | 9.12M |
| EBITDA | -20.25M | -17.84M | -20.99M | -15.58M | -12.74M | -4.79M |
| Net Income | -20.79M | -18.91M | -22.09M | -16.54M | -15.32M | -9.11M |
Balance Sheet | ||||||
| Total Assets | 30.07M | 39.19M | 42.66M | 55.49M | 65.58M | 29.64M |
| Cash, Cash Equivalents and Short-Term Investments | 12.39M | 20.10M | 23.14M | 37.49M | 54.11M | 20.10M |
| Total Debt | 3.44M | 3.57M | 13.94M | 11.99M | 12.28M | 24.24M |
| Total Liabilities | 10.08M | 13.80M | 21.49M | 18.60M | 16.79M | 27.26M |
| Stockholders Equity | 19.99M | 25.39M | 21.17M | 36.89M | 48.79M | 2.38M |
Cash Flow | ||||||
| Free Cash Flow | -11.74M | -9.22M | -14.77M | -17.31M | -12.87M | -8.29M |
| Operating Cash Flow | -11.28M | -8.95M | -13.72M | -16.17M | -12.70M | -7.81M |
| Investing Cash Flow | -458.00K | -275.00K | 8.95M | -10.74M | -168.00K | -482.00K |
| Financing Cash Flow | -11.23M | 6.19M | 296.00K | 409.00K | 46.88M | 22.69M |
ClearPoint Neuro Technical Analysis
ClearPoint Neuro Risk Analysis
ClearPoint Neuro Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $355.65M | ― | -7.46% | ― | -3.31% | -199.23% | |
60 Neutral | $237.83M | 15.29 | 8.12% | ― | 5.96% | -43.83% | |
59 Neutral | $318.26M | ― | -76.21% | ― | 23.22% | 9.54% | |
51 Neutral | $7.50B | 0.32 | -61.87% | 2.27% | 17.10% | 1.59% | |
50 Neutral | $343.73M | ― | -128.49% | ― | 22.05% | 29.86% | |
48 Neutral | $339.85M | ― | -30.11% | ― | 15.32% | 15.73% | |
47 Neutral | $387.11M | ― | -177.29% | ― | -23.99% | -100.40% |
ClearPoint Neuro Corporate Events
On June 16, 2025, ClearPoint Neuro, Inc. entered into a lease agreement with BRE-BMR SCD LLC to expand into a 30,171 square foot life science building in San Diego, California. This expansion will be executed in three phases, with the first phase expected to be occupied by June 13, 2025, and the final phase by July 1, 2026. The lease term is set for 132 months from the last phase’s occupation, with an option to extend for an additional five years. The initial monthly base rent is $5.95 per square foot, with specific abatement periods and annual increases of 3%. ClearPoint Neuro is also responsible for operating expenses and must provide a letter of credit as security.
The most recent analyst rating on (CLPT) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.
On May 21, 2025, ClearPoint Neuro, Inc. held its annual stockholders meeting where several key proposals were approved. These included the election of eight directors, the ratification of Cherry Bekaert LLP as the independent public accounting firm, and the approval of executive compensation and its voting frequency. Additionally, the stockholders approved the Amended and Restated 2021 Employee Stock Purchase Plan and the Sixth Amended and Restated 2013 Incentive Compensation Plan. These approvals are expected to impact the company’s governance and compensation strategies moving forward.
The most recent analyst rating on (CLPT) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.
ClearPoint Neuro, Inc. has revised its Non-Employee Director Compensation Plan to attract and retain qualified board members by offering appropriate compensation. The updated plan, last revised on May 22, 2023, reflects the company’s commitment to strong corporate governance practices.
The most recent analyst rating on (CLPT) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.
On May 13, 2025, ClearPoint Neuro reported its financial results for the first quarter of 2025, highlighting a record revenue of $8.5 million, marking an 11% increase from the previous year. The company experienced significant growth in its single-use navigation and therapy products, with a 70% increase in neurosurgery navigation and therapy revenue and a 104% rise in consumable product revenue. The FDA clearance of ClearPoint 3.0 Software contributed to this growth, enhancing operating room navigation and laser therapy capabilities. Despite capital market volatility, ClearPoint secured a long-term credit facility and equity investment, strengthening its financial position to achieve strategic objectives.
The most recent analyst rating on (CLPT) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.
On May 12, 2025, ClearPoint Neuro announced a significant financial arrangement with Oberland Capital, securing up to $110 million in investment. This includes a $105 million note financing and a $3.5 million stock purchase, aimed at supporting the company’s growth in cell and gene therapy markets. The proceeds will be used for general corporate purposes, including capital expenditures and working capital. This partnership is expected to bolster ClearPoint Neuro’s ability to meet the demands of its pharmaceutical partners and expand its product offerings, thereby enhancing its market position in the medical technology industry.
The most recent analyst rating on (CLPT) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.